Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group Inc (NQ: REPL )

16.38 -0.40 (-2.38%)
Streaming Delayed Price Updated: 12:09 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,240
Open 16.70
Bid (Size) 16.37 (4)
Ask (Size) 16.40 (2)
Prev. Close 16.78
Today's Range 16.10 - 16.50
52wk Range 15.51 - 29.52
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Replimune Group
Via Benzinga
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire

Performance

YTD
-37.84%
-37.84%
1 Month
-20.29%
-20.29%
3 Month
-29.94%
-29.94%
6 Month
-14.86%
-14.86%
1 Year
+1.74%
+1.74%

More News

Read More
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
Via Investor's Business Daily
Analyst Ratings for Replimune Group
Via Benzinga
Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session
Via Investor Brand Network
Recap: Replimune Group Q4 Earnings
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
Replimune Group: Q2 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
Via Investor's Business Daily
Analyst Ratings for Replimune Group
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
Via Benzinga
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
Via Benzinga
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday
Via Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Via Benzinga
Replimune Group: Q4 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.